Mena FN

Malignant Ascites Pipeline 2025: Pioneering Clinical Developments By 5+ Global Leaders Delveinsight Featuring Companies Such As Clover Biopharmaceuticals, YZY Biopharma ...

"Malignant Ascites Pipeline 2025"DelveInsight's,“Malignant Ascites Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant Ascites ...
Business Wire

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature ...
Nature

Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer

Paracentesis for malignant ascites is usually performed as an in-patient procedure, with a median length of stay (LoS) of 3–5 days, with intermittent clamping of the drain due to a perceived risk of ...
ascopubs.org

Predictors of early readmission to hospital and mortality in patients with malignant ascites: Analysis of the nationwide readmissions database.

Weight management following endometrial cancer treatment: A pilot trial to evaluate the efficacy of the profile by Sanford program. The GET FIT trial (NCT01635413): A randomized controlled trial of ...
阿思達克財經網

YZYBIO-B (02496.HK) M701 NDA for Malignant Ascites Accepted

YZYBIO-B (02496.HK) announced that the New Drug Application (NDA) for its self-developed bispecific antibody M701, indicated for malignant ascites caused by advanced epithelial mal... Open a new ...
Finanznachrichten

Lindis Biotech GmbH: Lindis Biotech and Pharmanovia Announce European Marketing Authorization Approval for Catumaxomab, A First-In-Class Treatment for Malignant Ascites

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEMENT, LINDIS HAS GRANTED PHARMANOVIA THE ...
ascopubs.org

The trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population).

VEGF pathway therapy: Resampling positive phase III data to assess phase II trial designs and endpoints. Background: Malignant ascites (MA) is a symptom of late-stage tumor disease and associated with ...
Business Wire

Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites

BASILDON, England--(BUSINESS WIRE)--Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has ...
Medscape

Hematological Malignancy Manifesting as Ascites

Splenomegaly resulting from portal hypertension can be caused by cirrhosis, hepatic venous outflow tract obstruction and extrahepatic portal vein obstruction. Both cirrhosis and hepatic venous outflow ...
National Institute for Health and Care Excellence

PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites

The conventional management of treatment-resistant, recurrent malignant ascites involves repeated large-volume paracentesis (needle drainage of fluid) procedures that are carried out in hospital. Most ...